A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Sponsor
GlaxoSmithKline
Study ID
NCT06897527
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Neoplasms, Endometrial

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.

Key Dates

Start date
Jul 15, 2025
Status verified
Jul 2025
Primary completion
Jan 13, 2027
Completion
Jan 13, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dostarlimab

Primary Outcome Measure

Number of Participants with Grade 3 or greater Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 25 weeks ]

Central Contacts